GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Piotroski F-Score

Merus NV (Merus NV) Piotroski F-Score

: 4 (As of Today)
View and export this data going back to 2016. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Merus NV has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Merus NV's Piotroski F-Score or its related term are showing as below:

MRUS' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 5
Current: 4

During the past 12 years, the highest Piotroski F-Score of Merus NV was 5. The lowest was 1. And the median was 4.


Merus NV Piotroski F-Score Historical Data

The historical data trend for Merus NV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.00 5.00 1.00 4.00

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 2.00 3.00 4.00

Competitive Comparison

For the Biotechnology subindustry, Merus NV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Merus NV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Merus NV's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -39.741 + -32.033 + -23.012 + -60.153 = $-154.94 Mil.
Cash Flow from Operations was -36.743 + -41.586 + -27.53 + -36.348 = $-142.21 Mil.
Revenue was 13.499 + 10.476 + 11.033 + 8.939 = $43.95 Mil.
Gross Profit was 13.499 + 10.476 + 11.033 + 8.939 = $43.95 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(376.542 + 338.52 + 363.624 + 492.186 + 455.494) / 5 = $405.2732 Mil.
Total Assets at the begining of this year (Dec22) was $376.54 Mil.
Long-Term Debt & Capital Lease Obligation was $10.49 Mil.
Total Current Assets was $368.81 Mil.
Total Current Liabilities was $69.09 Mil.
Net Income was -18.893 + -5.714 + -24.615 + -81.972 = $-131.19 Mil.

Revenue was 11.655 + 12.684 + 6.581 + 10.666 = $41.59 Mil.
Gross Profit was 11.655 + 12.684 + 6.581 + 10.666 = $41.59 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(456.6 + 417.5 + 444.793 + 414.99 + 376.542) / 5 = $422.085 Mil.
Total Assets at the begining of last year (Dec21) was $456.60 Mil.
Long-Term Debt & Capital Lease Obligation was $11.79 Mil.
Total Current Assets was $306.44 Mil.
Total Current Liabilities was $78.93 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Merus NV's current Net Income (TTM) was -154.94. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Merus NV's current Cash Flow from Operations (TTM) was -142.21. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-154.939/376.542
=-0.41147867

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-131.194/456.6
=-0.28732808

Merus NV's return on assets of this year was -0.41147867. Merus NV's return on assets of last year was -0.28732808. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Merus NV's current Net Income (TTM) was -154.94. Merus NV's current Cash Flow from Operations (TTM) was -142.21. ==> -142.21 > -154.94 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=10.488/405.2732
=0.02587884

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=11.79/422.085
=0.02793276

Merus NV's gearing of this year was 0.02587884. Merus NV's gearing of last year was 0.02793276. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=368.814/69.089
=5.33824487

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=306.443/78.926
=3.88266224

Merus NV's current ratio of this year was 5.33824487. Merus NV's current ratio of last year was 3.88266224. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Merus NV's number of shares in issue this year was 57.824. Merus NV's number of shares in issue last year was 46.32. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=43.947/43.947
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=41.586/41.586
=1

Merus NV's gross margin of this year was 1. Merus NV's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=43.947/376.542
=0.11671208

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=41.586/456.6
=0.09107753

Merus NV's asset turnover of this year was 0.11671208. Merus NV's asset turnover of last year was 0.09107753. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Merus NV has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Merus NV  (NAS:MRUS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Merus NV Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Merus NV's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM